T1	PROC 46 66	Estudio de extensión
T2	CHEM 84 92	Avelumab
#1	AnnotatorNotes T2	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	PROC 115 162	Estudio abierto, multicéntrico y de seguimiento
T4	PROC 228 245	estudios clínicos
#2	AnnotatorNotes T4	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T5	CHEM 250 258	avelumab
#3	AnnotatorNotes T5	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	DISO 296 311	Tumores sólidos
#4	AnnotatorNotes T6	C0280100; Solid Neoplasm; Neoplastic Process
T7	PROC 373 384	tratamiento
#5	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T8	PROC 391 406	estudio clínico
#6	AnnotatorNotes T8	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T9	CHEM 410 418	avelumab
#7	AnnotatorNotes T9	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	CHEM 518 526	avelumab
#8	AnnotatorNotes T10	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	PROC 538 549	tratamiento
#9	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	CHEM 561 569	avelumab
#10	AnnotatorNotes T12	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	PROC 578 606	seguimiento de supervivencia
T14	PROC 633 644	tratamiento
#11	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	PROC 668 679	tratamiento
#12	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	CHEM 718 733	anticonceptivos
#13	AnnotatorNotes T16	C0009871; Contraceptive Agents; Pharmacologic Substance
T17	PROC 1007 1018	tratamiento
#14	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	DISO 1027 1044	hipersensibilidad
#15	AnnotatorNotes T18	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T19	CHEM 1074 1086	ingredientes
#16	AnnotatorNotes T19	C1550600; Ingredient; Chemical Viewed Functionally
T20	PROC 1090 1102	intervención
#17	AnnotatorNotes T20	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T21	CHEM 260 271	MSB0010718C
#18	AnnotatorNotes T21	C3896806; MSB0010718C; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T22	CHEM 1193 1201	avelumab
#19	AnnotatorNotes T22	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T23	CHEM 1259 1267	avelumab
#20	AnnotatorNotes T23	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	Date 13 17	2018
T25	Date 184 197	a largo plazo
T26	Date 472 483	actualmente
T27	Date 607 620	a largo plazo
T29	Spec_cue 881 890	riesgo de
T32	LIVB 1333 1345	investigador
#21	AnnotatorNotes T32	C0035173; Research Personnel; Professional or Occupational Group
T34	PHYS 945 956	embarazadas
#22	AnnotatorNotes T34	C0032961; Pregnancy; Organism Function
T28	LIVB 651 664	participantes
#23	AnnotatorNotes T28	C4554048; Study Participant; Population Group
T30	LIVB 831 867	participantes masculinos y femeninos
#24	AnnotatorNotes T30	C4554048; Study Participant; Population Group + C0043210; Woman; Population Group + C0025266; Male population group; Population Group
T36	PHYS 891 901	concepción
#25	AnnotatorNotes T36	C0009637; Conception; Organism Function | C0015914; Fertilization; Organism Function
T37	PHYS 973 982	lactancia
#26	AnnotatorNotes T37	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T31	LIVB 931 982	Participantes embarazadas o en periodo de lactancia
#27	AnnotatorNotes T31	C0033011; Pregnant Women; Population Group | C4316174; Patients who are breastfeeding; Patient or Disabled Group
T33	LIVB 986 999	Participantes
#28	AnnotatorNotes T33	C4554048; Study Participant; Population Group
T35	LIVB 1120 1132	participante
#29	AnnotatorNotes T35	C4554048; Study Participant; Population Group
T38	LIVB 1207 1219	participante
#30	AnnotatorNotes T38	C4554048; Study Participant; Population Group
T39	LIVB 1361 1373	participante
#31	AnnotatorNotes T39	C4554048; Study Participant; Population Group
T40	LIVB 204 217	participantes
#32	AnnotatorNotes T40	C4554048; Study Participant; Population Group
T41	LIVB 458 471	participantes
#33	AnnotatorNotes T41	C4554048; Study Participant; Population Group
T42	LIVB 340 353	Participantes
#34	AnnotatorNotes T42	C4554048; Study Participant; Population Group
A1	Assertion T36 Speculated
A2	Status T18 History_of
A3	Status T10 History_of
A4	Status T22 History_of
A5	Status T23 History_of
#35	AnnotatorNotes T3	C1709323; Open Label Study; Research Activity + C1096776; Multicenter Study; Research Activity + C3274571; Clinical Study Follow-up; Health Care Activity 
#36	AnnotatorNotes T25	C0443252; Long-term; Temporal Concept
#37	AnnotatorNotes T27	C0443252; Long-term; Temporal Concept
#38	AnnotatorNotes T26	C0521116; Current (present time); Temporal Concept 
T43	Neg_cue 1347 1353	impida
T44	Observation 1374 1397	participe en el estudio
A6	Assertion T44 Negated
#39	AnnotatorNotes T44	C1278516; Patient participation status; Finding
R1	Negation Arg1:T43 Arg2:T44	
T46	PROC 1241 1248	estudio
#40	AnnotatorNotes T46	C0681814; research study; Research Activity
T45	Observation 1228 1248	retirado del estudio
#41	AnnotatorNotes T45	C0422727; Patient withdrawn from trial; Finding (?)
A7	Status T46 History_of
T47	CONC 178 183	datos
#42	AnnotatorNotes T47	C1511726; Data; Idea or Concept
R4	Overlap Arg1:T47 Arg2:T25	
R5	Experiences Arg1:T40 Arg2:T5	
R6	Experiences Arg1:T40 Arg2:T21	
R7	Experiences Arg1:T42 Arg2:T7	
R8	Used_for Arg1:T9 Arg2:T7	
T48	Observation 484 507	inscritos en un estudio
#43	AnnotatorNotes T48	C1278516; Patient participation status; Finding (?)
R9	Overlap Arg1:T48 Arg2:T26	
R11	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T48	
R12	Experiences Arg1:T41 Arg2:T11	
R13	Used_for Arg1:T12 Arg2:T11	
R14	Overlap Arg1:T48 Arg2:T11	
A8	Status T48 History_of
T49	Quantifier_or_Qualifier 550 556	activo
#44	AnnotatorNotes T49	C0679217; Active State; Idea or Concept
R15	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T49	
R16	Overlap Arg1:T13 Arg2:T27	
R17	After Arg1:T13 Arg2:T14	
R18	Experiences Arg1:T41 Arg2:T14	
T50	Quantifier_or_Qualifier 680 686	activo
#45	AnnotatorNotes T50	C0679217; Active State; Idea or Concept
R19	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T50	
R20	Experiences Arg1:T28 Arg2:T15	
R21	Experiences Arg1:T28 Arg2:T16	
T51	Quantifier_or_Qualifier 734 753	altamente efectivos
R22	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T51	
R23	Experiences Arg1:T30 Arg2:T36	
R24	Speculation Arg1:T29 Arg2:T36	
R25	Experiences Arg1:T30 Arg2:T16	
R26	Experiences Arg1:T30 Arg2:T15	
R27	Experiences Arg1:T28 Arg2:T36	
R28	Experiences Arg1:T31 Arg2:T34	
R29	Experiences Arg1:T31 Arg2:T37	
T52	Quantifier_or_Qualifier 1019 1025	activo
#46	AnnotatorNotes T52	C0679217; Active State; Idea or Concept
R30	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T52	
R31	Experiences Arg1:T33 Arg2:T17	
R32	Experiences Arg1:T33 Arg2:T18	
R33	Causes Arg1:T19 Arg2:T18	
R34	Used_for Arg1:T19 Arg2:T20	
R35	Experiences Arg1:T33 Arg2:T19	
R36	Experiences Arg1:T35 Arg2:T22	
R37	Experiences Arg1:T38 Arg2:T23	
R2	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T45	
R3	Experiences Arg1:T41 Arg2:T10	
R10	Used_for Arg1:T10 Arg2:T11	
A9	Experiencer T39 Patient
A10	Experiencer T32 Other
A11	Experiencer T38 Patient
A12	Experiencer T35 Patient
A13	Experiencer T33 Patient
A14	Experiencer T31 Patient
A15	Experiencer T30 Patient
A16	Experiencer T40 Patient
A17	Experiencer T42 Patient
A18	Experiencer T41 Patient
A19	Experiencer T28 Patient
